Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation. Fukuoka Bone Marrow Transplantation Group.

Abstract:

:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplantation, sufficient PBSC or PBPC must be infused. To confirm the utility of granulocyte colony-stimulating factor (G-CSF) in chemotherapy-induced PBSC mobilization, we investigated the effect of G-CSF on PBSC mobilization in leukemia and lymphoma patients. The study design was such that PBSC mobilization with and without G-CSF was assessed in the same patients. The results indicate that PBSC mobilization can be enhanced significantly when G-CSF is given during the recovery phase postchemotherapy. Interestingly, progenitor cells of different lineages could be mobilized by G-CSF. We subsequently investigated the effect of increasing G-CSF dose on PBSC mobilization during steady-state hematopoiesis in healthy adult donors. The results indicate that not only committed but also primitive progenitor cells are mobilized into the circulation in a dose-and time-dependent manner when G-CSF at 5, 10, or 15 micrograms/kg was given on each of 5 days and leukapheresis was performed on day 6. From our data we estimate that sufficient PBSC for engraftment after allogeneic PBSC transplantation can be collected on day 5 of administration of G-CSF at 10 micrograms/kg and by 10-1 leukapheresis on days 5 and 6. Furthermore, we found that some G-CSF-mobilized PBSC retained their self-renewal capability. These observations suggest that hematopoietic stem cells for allogeneic PBSC transplantation can be mobilized by short-term administration of relatively high-dose G-CSF.

authors

Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

doi

10.1007/s002800051051

subject

Has Abstract

pub_date

1996-01-01 00:00:00

pages

S115-9

eissn

0344-5704

issn

1432-0843

journal_volume

38 Suppl

pub_type

杂志文章
  • Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines.

    abstract:PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800100278

    authors: Du YH,Ho PC

    更新日期:2001-06-01 00:00:00

  • Inhibition of human breast cancer colony formation by anticalmodulin agents: trifluoperazine, W-7, and W-13.

    abstract::The effects of anticalmodulin agents, namely trifluoperazine (TFP) and two naphthalene sulfonamide derivatives (W-7 and W-13), were tested on the growth of a human breast cancer cell line (MDA-MB-231) using a soft agar clonogenic assay. The results of this in vitro study reveal that TFP, W-7, and W-13 had the ability ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254251

    authors: Wei JW,Hickie RA,Klaassen DJ

    更新日期:1983-01-01 00:00:00

  • Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

    abstract:PURPOSE:To evaluate the effect of front-line chemotherapy on CK-19mRNA+ circulating tumor cells (CTCs) and their relevance in patients with metastatic breast cancer (MBC). PATIENTS AND METHODS:The presence of CK-19mRNA+ CTCs was assessed using a real-time RT-PCR assay in 298 previously untreated patients with MBC befo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-014-2598-2

    authors: Georgoulias V,Apostolaki S,Bozionelou V,Politaki E,Perraki M,Georgoulia N,Kalbakis K,Kotsakis A,Xyrafas A,Agelaki S,Mavroudis D

    更新日期:2014-12-01 00:00:00

  • Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.

    abstract:PURPOSE:Our study was designed to evaluate the efficacy and safety of everolimus in patients with pre-treated metastatic gastric and esophagus cancers in a US-based population focusing on biomarker correlation. METHODS:Patients with advanced upper GI adenocarcinomas who progressed after 1-2 prior regimens received eve...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-015-2744-5

    authors: Wainberg ZA,Soares HP,Patel R,DiCarlo B,Park DJ,Liem A,Wang HJ,Yonemoto L,Martinez D,Laux I,Brennan M,Hecht JR

    更新日期:2015-07-01 00:00:00

  • Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.

    abstract::Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been pub...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3320-y

    authors: Thiery-Vuillemin A,Orillard E,Mouillet G,Calcagno F,Devillard N,Bouchet S,Royer B

    更新日期:2017-06-01 00:00:00

  • 6-ethylmercaptopurine-mediated growth inhibition of HL-60 cells in vitro irrespective of purine salvage.

    abstract::A variety of purine analogs inhibit the growth and induce the differentiation of human promyelocytic leukemia (HL-60) cells that lack the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). Mechanisms by which purine analogs induce differentiation offer unique potential for cancer chemotherap...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689581

    authors: Gibboney DS,French BT,Patrick DE,Trewyn RW

    更新日期:1989-01-01 00:00:00

  • Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells.

    abstract::The mechanism of toxicity of 3-deazaguanosine was studied in a number of human tumor cell lines by determination of the effects of various purine compounds on the growth of the cells in the presence of the drug and by studies of the effects of 3-deazaguanosine on the metabolism of radiolabeled precursors in these cell...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257296

    authors: Page T,Jacobsen SJ,Smejkal RM,Scheele J,Nyhan WL,Mangum JH,Robins RK

    更新日期:1985-01-01 00:00:00

  • A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.

    abstract:PURPOSE:Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03908-0

    authors: Peer CJ,Schmidt KT,Kindrick JD,Eisner JR,Brown VV,Baskin-Bey E,Madan R,Figg WD

    更新日期:2019-10-01 00:00:00

  • Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.

    abstract:PURPOSE:In vitro and in vivo preclinical models have demonstrated synergistic activity when topoisomerase I and II inhibitors are administered sequentially. Topoisomerase I inhibitors increase topoisomerase II levels and increase cell kill induced by topoisomerase II poisons. We evaluated this hypothesis in a cohort of...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002800000211

    authors: Dowlati A,Levitan N,Gordon NH,Hoppel CL,Gosky DM,Remick SC,Ingalls ST,Berger SJ,Berger NA

    更新日期:2001-01-01 00:00:00

  • Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.

    abstract::The purpose of this study was to evaluate the response rate, methotrexate plasma levels, and toxicity of a three-drug regimen in patients with gastric carcinoma. A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF). Adriamyci...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254103

    authors: Ajani JA,Goudeau P,Levin B,Faintuch JS,Abbruzzese JL,Boman BM,Kanojia MD

    更新日期:1989-01-01 00:00:00

  • Preliminary results of chemo-radiotherapy followed or not by active immunotherapy of stage III and IV lymphosarcoma and reticulosarcoma. Correlation of the results with WHO categorisation.

    abstract::We treated 101 patients with advanced (stage III and IV) lymphosarcoma and reticulosarcoma at first presentation of the disease or in relapse according to a protocol combining initial chemotherapy, complementary radiotherapy on icebergs, supplementary chemotherapy, and, finally, active immunotherapy. The overall compl...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00257149

    authors: Misset JL,Mathé G,Tubiana M,Caillou B,de Vassal F,Pouillart P,Gil M,Tentas C,Hayat M,Schwarzenberg L,Jasmin C,Delgado M,Machover D,Ribaud P,Musset M

    更新日期:1978-01-01 00:00:00

  • Positive relationship between subsequent chemotherapy and overall survival in pancreatic cancer: meta-analysis of postprogression survival for first-line chemotherapy.

    abstract:PURPOSE:To gain a better understanding of the impact of postprogression survival (PPS) and post-trial anticancer therapy on overall survival (OS) in first-line pancreatic cancer patients. METHODS:A literature search identified 54 randomized trials, focusing on gemcitabine monotherapy to eliminate effects of heterogene...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s00280-017-3263-3

    authors: Kasuga A,Hamamoto Y,Takeuchi A,Kawasaki K,Suzuki T,Hirata K,Sukawa Y,Takaishi H,Kanai T

    更新日期:2017-03-01 00:00:00

  • Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL).

    abstract:PURPOSE:To investigate the antitumor effects of tyroserleutide (tyrosyl-seryl-leucine, YSL) on human Bel7402 hepatocarcinoma in vitro and in vivo, with preliminary exploration of its antitumor mechanism. METHODS:MTT was used to observe the anticarcinogenic effects of YSL on human hepatocarcinoma Bel7402 cells in vitro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-0046-z

    authors: Lu R,Jia J,Bao L,Fu Z,Li G,Wang S,Wang Z,Jin M,Gao W,Yao Z

    更新日期:2006-01-01 00:00:00

  • Flavone acetic acid and plasma protein binding.

    abstract::Both the capacity of healthy human, cancer patient, and mouse plasma proteins to bind flavone acetic acid (FAA) and the qualitative differences in the plasma protein-binding site were studied. The binding capacity of plasma proteins for FAA was saturated within the therapeutic range in both species. The binding of FAA...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689272

    authors: Brodfuehrer J,Valeriote F,Chan K,Heilbrun L,Corbett T

    更新日期:1990-01-01 00:00:00

  • Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.

    abstract::Brain tumor lacks effective delivery system for treatment. Focused ultrasound (FUS) can reversibly open BBB without impacts on normal tissues. As a potential drug carrier, cationic liposomes (CLs) have the ability to passively accumulate in tumor tissues for their positive charge. In this study, FUS introduced doxorub...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-015-2926-1

    authors: Lin Q,Mao KL,Tian FR,Yang JJ,Chen PP,Xu J,Fan ZL,Zhao YP,Li WF,Zheng L,Zhao YZ,Lu CT

    更新日期:2016-02-01 00:00:00

  • Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

    abstract::Clinical evidence suggests some lack of cross resistance between vincristine (VCR) and vindesine (VDS). To investigate this phenomenon experimentally, drug-resistant L5178Y lymphoblast cell lines have been derived in vitro. These lines, under conditions of continuous drug exposure, exhibit a 50-fold order of resistanc...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00255477

    authors: Hill BT,Whelan RD

    更新日期:1982-01-01 00:00:00

  • Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice.

    abstract:PURPOSE:This study was conducted to define the activity of irofulven in the treatment of a series of xenografts derived from human glioblastoma multiforme growing subcutaneously and intracranially in athymic nude mice. METHODS:Athymic mice bearing subcutaneous or intracranial tumors were treated with irofulven at a 10...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800100358

    authors: Friedman HS,Keir ST,Houghton PJ,Lawless AA,Bigner DD,Waters SJ

    更新日期:2001-11-01 00:00:00

  • Phase I and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer.

    abstract:PURPOSE:We conducted phase I and tolerability studies to determine the maximum tolerated dose (MTD) and recommended dose of nab-paclitaxel when administered weekly with solid tumors and to evaluate the tolerability of weekly administration at a dose of 150 mg/m(2) with metastatic breast cancer (MBC) as a first-line the...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-011-1726-5

    authors: Ando M,Yonemori K,Katsumata N,Shimizu C,Hirata T,Yamamoto H,Hashimoto K,Yunokawa M,Tamura K,Fujiwara Y

    更新日期:2012-02-01 00:00:00

  • Disruption of CTLA-4 expression on peripheral blood CD8 + T cell enhances anti-tumor efficacy in bladder cancer.

    abstract::Activation of programmed death-1 (PD-1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) on T cells leads to T cell exhaustion and ultimately facilitates tumor progression. Recent success of using immune cell checkpoint inhibitors offers a great promise to treat various cancers, including bladder cancer. However, the exp...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03800-x

    authors: Zhang W,Shi L,Zhao Z,Du P,Ye X,Li D,Cai Z,Han J,Cai J

    更新日期:2019-05-01 00:00:00

  • In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.

    abstract:PURPOSE:To compare the in vitro cytotoxicity of nedaplatin, an investigational platinum analog, with that of the standard platinum agents, cisplatin and carboplatin, against fresh human, epithelial ovarian cancers. METHODS:The Hamburger-Salmon human tumor colony-forming assay (HTCA) was used to measure the chemosensit...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050604

    authors: Alberts DS,Fanta PT,Running KL,Adair LP Jr,Garcia DJ,Liu-Stevens R,Salmon SE

    更新日期:1997-01-01 00:00:00

  • Comparison of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis.

    abstract::Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00688329

    authors: Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

    更新日期:1996-01-01 00:00:00

  • Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients.

    abstract::Melphalan (L-PAM) pharmacokinetics were investigated in nine ovarian cancer patients before and after cisplatin (DDP) treatment. When L-PAM was given 24 h before DDP, the elimination half-life (t 1/2 beta), plasma clearance (Clp), and volume of distribution (Vd beta) of L-PAM were, respectively: 46.4 +/- 6.7 min, 20.5...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00254189

    authors: Zucchetti M,D'Incalci M,Willems Y,Cavalli F,Sessa C

    更新日期:1988-01-01 00:00:00

  • Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.

    abstract:PURPOSE:Following a previously published pre-clinical validation, this phase I study evaluated the safety, maximum tolerated dose, anti-tumour activity and immune status of a gemcitabine-chloroquine combination as a first- or late-line treatment in patients with metastatic or unresectable pancreatic cancer. METHODS:In...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-017-3446-y

    authors: Samaras P,Tusup M,Nguyen-Kim TDL,Seifert B,Bachmann H,von Moos R,Knuth A,Pascolo S

    更新日期:2017-11-01 00:00:00

  • The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro.

    abstract:PURPOSE:It has recently been recognised that anticancer chemotherapy can elicit an immunogenic form of apoptosis characterised by the exposure of calreticulin (CRT) on the surface of dying tumour cells, entailing an immune response that contributes to the therapeutic outcome. CRT exposure has been found to be induced b...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-010-1302-4

    authors: Sonnemann J,Gressmann S,Becker S,Wittig S,Schmudde M,Beck JF

    更新日期:2010-08-01 00:00:00

  • Irinotecan induces enterocyte cell death and changes to muc2 and muc4 composition during mucositis in a tumour-bearing DA rat model.

    abstract::Irinotecan-induced mucositis is a major oncological problem. Goblet cells secrete mucus, protecting the intestinal mucosa, with secretion altered during mucositis. The enteric nervous system is involved in regulating gut motility and secretion. The aim of this study was to determine whether enteric neural cells and go...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03787-5

    authors: Thorpe D,Sultani M,Stringer A

    更新日期:2019-05-01 00:00:00

  • Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery.

    abstract:PURPOSE:Angiotensin (1-7) [A(1-7)] is a bioactive peptide of the renin angiotensin system that stimulates the number of bone marrow progenitors and hematopoietic recovery after myelosuppression. We evaluated the combination of A(1-7) with colony-stimulating factors, Neupogen and Epogen, on bone marrow progenitors and t...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-013-2312-9

    authors: Rodgers KE,Espinoza TB,Roda N,Meeks CJ,diZerega GS

    更新日期:2013-12-01 00:00:00

  • Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

    abstract:OBJECTIVE:Docetaxel given orally as monotherapy results in low bioavailability of <10%. Previous studies have indicated that the intestinal efflux pump P-glycoprotein (P-gp) prevents uptake from the gut resulting in low systemic exposure to docetaxel. The purpose of this study was to determine the degree of enhancement...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s00280-004-0864-4

    authors: Kuppens IE,Bosch TM,van Maanen MJ,Rosing H,Fitzpatrick A,Beijnen JH,Schellens JH

    更新日期:2005-01-01 00:00:00

  • Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate.

    abstract::The local therapeutic effects and 5-year survival rates obtained following subsegmental transcatheter arterial embolization (TAE) therapy for small hepatocellular carcinomas (HCCs) were retrospectively analyzed. A total of 124 nodular-type HCC lesions measuring less than 4 cm in diameter in 100 patients with liver cir...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686674

    authors: Matsui O,Kadoya M,Yoshikawa J,Gabata T,Takashima T,Demachi H

    更新日期:1994-01-01 00:00:00

  • Synergistic interaction between cisplatin and tamoxifen delays the emergence of cisplatin resistance in head and neck cancer cell lines.

    abstract::The interaction between cisplatin (cDDP) and tamoxifen (TAM) was evaluated in the human head and neck squamous-carcinoma cell lines UM-SCC-10B and UM-SCC-5. Synergy between cDDP and TAM was demonstrated in the UM-SCC-10B cell line. Concordant with the synergistic effect between cDDP and TAM, the rate of development of...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686837

    authors: Nakata B,Albright KD,Barton RM,Howell SB,Los G

    更新日期:1995-01-01 00:00:00

  • Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.

    abstract::A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050614

    authors: Looby M,Linke R,Weiss M

    更新日期:1997-01-01 00:00:00